Abstract Oridonin, isolated from Rabdosia rubescens, has been proven to possess various anti-neoplastic and antiinflammatory properties. Previously, we reported the antifibrogenic effects of oridonin for liver in vitro. In the present study, we investigated the effects of a newly designed analog CYD0692 in vitro. Cell viability was measured by Alamar Blue assay. Cell apoptosis was assessed by Cell Death ELISA and Yo-Pro-1 staining. Western blots were performed for cellular proteins. Flow cytometry was used to measure cell cycle regulation. CYD0692 significantly inhibited LX-2 cells proliferation in a dose-and time-dependent manner with an IC 50 value of *0.7 lM for 48 h, *tenfold greater potency than oridonin. Similar results were observed in HSC-T6 cells. In contrast, on the human hepatocyte cell line C3A, only 12 % of the cell growth was inhibited with 5 lM of CYD0692 treatment for 48 h, while 30 % inhibited at 10 lM. After CYD0692 treatment on LX-2 cells, apoptosis and S-phase cell cycle arrest were induced; cleaved-PARP, p21, and p53 were activated while cyclin-B1 levels declined. In addition, a-smooth muscle actin, type I Collagen, and fibronectin (FN) were markedly down regulated. Transforming growth factor b1 (TGF b1) has been identified as a dominant stimulator for ECM production in HSC. Our results indicated that pretreatment with CYD0692 blocked TGF b1-induced FN expression, thereby decreasing the downstream factors of TGF b1 signaling, such as Phospho-Smad2/3 and phospho-ERK. In comparison with oridonin, its novel derivative CYD0692 has demonstrated to be a more potent and potentially safer anti-fibrogenic agent for the treatment of hepatic fibrosis.
Introduction
Persistent liver injury results in chronic liver disease (CLD) due to unrelenting activation of the fibrotic pathway. Worldwide viral hepatitis is the leading cause of CLD followed by toxin induced (e.g., alcohol), altered metabolic condition, and autoimmune etiologies. Uncorrected fibrosis is considered as the driving force leading to cirrhosis. Thirty-one million disability-adjusted life years (DALYs) and 2 % of all deaths were due to liver cirrhosis in 2010 [1] . Liver fibrosis, if left untreated, leads to cirrhosis that is part of a dynamic wound healing process with phases of extracellular matrix (ECM) protein deposition and degradation [2, 3] . When there is a net positive deposition of ECM, liver fibrosis progresses.
Activated hepatic stellate cells (HSC) are the major source of ECM proteins within the liver [2] . Quiescent HSC reside within the space of Disse and comprise 2-10 % of the cell population [4] . Quiescent HSC become activated HSC following a variety of stimuli such as transforming growth factor b1 (TGF b1), lipopolysaccharide (LPS)/tolllike receptors, tissue hypoxia, platelet-derived growth factors (PDGF), nicotinamide adenine dinucleotide phosphate-oxidase (NADPH), and the renin-angiotensin system [5, 6] . This activation is characterized by over expression of a-smooth muscle actin (a-SMA), excessive production of collagen Type I and III, chemokines, adhesion molecules and presentation of antigens to T cells and Natural Killer (NK) cells [7] [8] [9] [10] .
Currently available treatment is focused on elimination of the etiological agent, but alleviation of HSC activation may supplement therapy [11] . We have previously reported that oridonin, an active compound isolated from Rabdosia rubescens, inhibits HSC proliferation and fibrogenesis [12] . Oridonin has demonstrated the ability to decrease HSC cell viability, increase apoptosis, and decrease both endogenous and TGF b1-stimulated ECM production by HSCs. While oridonin has been extensively studied in cancer treatment, previous work from our team indicated that design and development of novel oridonin analogs could generate more potent and safer compounds with better drug properties [13] [14] [15] [16] .
In the present study, we propose that CYD0692, a newly designed oridonin analog, exhibits more potent anti-fibrogenic effects by inhibiting HSC activation, proliferation, and ECM production in an in vitro model.
Methods

Reagents
All cell culture mediums and trypsin were purchased from Life Technology Corp. (Carlsbad, CA). Oridonin and antibody against a-smooth muscle actin (a-SMA) (Cat#5228) were purchased from Sigma-Aldrich Co. LLC. (St. Louis, MO). TGFb1 was purchased from R&D Systems Inc. (Minneapolis, MN). Propidium iodide was purchased from MP Biomedicals, LLC (Solon, OH). Antibodies against Fibronectin (sc-6952) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-Collagen Type I polyclonal antibody (600-401-103) was purchased from Rockland Immunochemicals Inc. (Gilbertsville, PA). GAPDH antibody (10R-G109A) was purchased from Fitzgerald Industries (Concord, MA). Antip21 (Cat#556431) was purchased from BD Biosciences (San Jose, CA). Anti-p53 (Cat#2527), phospho-p53 (Cat#9286), cleaved-PARP (Cat#5625), cleaved caspase-9 (Cat#9505), phospho-ERK 1/2 (Cat#4377), and phosphoSmad 2/3 (Cat#8828) were purchased from Cell Signaling Technology Inc. (Danvers, MA). Cleaved caspase-3 (ab136812) was purchased from Abcam plc. (Cambridge, MA).
CYD0692 is a novel analog designed with an additional a-formylenone motif formed in the A-ring and an acetonide moiety introduced at 7,14-dihydroxyl of oridonin (Fig. 1) . CYD0692 was synthesized following our previously reported protocols [13] .
Cell culture
The human immortalized HSC line LX-2 and rat immortalized HSC line HSC-T6 were obtained from Dr. Scott Friedman (Mount Sinai Medical Center, New York) and cultured at 37°C with 5 % CO 2 in Dulbecco's modified Eagle's medium (DMEM) with a high glucose concentration (4.5 g/L) supplemented with 5 % fetal bovine serum (FBS), 1 % penicillin/streptomycin. Human hepatocyte cell line C3A was obtained from American Type Cell Culture (ATCC, Manassas, VA), and maintained in DMEM medium containing 10 % FBS. All experiments were performed on cells within 6 weeks of culture from liquid nitrogen.
Western immunoblotting
Whole cell extracts were prepared as previously described [12] . Briefly, extracts were prepared using RIPA buffer (Thermo Fischer Scientific, Inc., Waltham, MA) with 1 % Halt protease inhibitor cocktail and 1 % Halt phosphatase inhibitor cocktails (Thermo Fischer Scientific, Inc., Waltham, MA). The protein concentration was measured and quantified by the Bradford method [17] . 10-30 lg of protein was fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Life Technologies Corporation, Grand Island, NY) under denaturing conditions and then electro-transferred to a polyvinylidene fluoride (PVDF) membrane. After being blocked with Blocking buffer (LI-COR, Inc., Lincoln, NE) the membrane was probed with the indicated primary antibody (Ab) diluted with blocking buffer. Membranes were washed three times with Phosphate-buffered saline with 0.1 % Tween 20 (PBST), and incubated 1 h with IRDye 680-conjugated anti-mouse l or IRDye 800-conjugated anti-rabbit Ab (LI-COR, Inc., Lincoln, NE). Finally, the membranes were washed three times with PBST, and signals were scanned and visualized by Odyssey Infrared Imaging System (LI-COR, Inc., Lincoln, NE).
Cell death detection ELISA assay 3 cells/well of C3A cells in 100 lL of complete medium were seeded into 96-well plates. Next day, cells reached 50-60 % confluence and were replaced with fresh complete medium and treated as indicated for 24, 48, or 72 h. Alamar blue stock solution (Life Technologies Corporation, Grand Island, NY) was diluted to 1:1 with culture medium and a volume of 25 lL/ well was transferred into the assay plate for final concentration of 10 % alamar blue. The plate was returned to the incubator for an additional 4 h. Fluorescence intensity was monitored using a SpectraMax M2 microplate reader (Molecular Devices, LLC, Sunnyvale, CA) with excitation and emission wavelengths set at 540 and 590 nm, respectively. Assay was performed in triplicate and repeated at least three times.
Cell cycle analysis by flow cytometry
Nuclear DNA content was measured using propidium iodide staining and fluorescence-activated cell sorter analysis. Briefly, 2 9 10 6 adherent cells were trypsinized, washed with phosphate-buffered saline, resuspended in a low-salt stain solution (3 % polyethylene glycol 8000, 50 lg of propidium iodide per mL, 0.1 % Triton X-100, 4 mM sodium citrate, 180 units of RNase A per mL), and incubated at 37°C for 20 min. An equal volume of highsalt stain solution (3 % polyethylene glycol 8000, 50 lg of propidium iodide per ml, 0.1 % Triton X-100, and 400 mM sodium chloride) was then added to the cell suspension. Propidium iodide-stained nuclei were stored at 4°C at least 3 h before fluorescence-activated cell sorter analysis using BD FACSCanto II flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ) at the University of Texas Medical Branch Flow Cytometry and Cell Sorting Core Facility. ModFit LT for Win32 software was used for data analysis (Verity Software House, Inc., Topsham, ME).
Statistical analysis
Statistical analysis was performed using GraphPad 6.0 (GraphPad Prism, GraphPad Software Inc. La Jolla, CA). All summary bar and line graphs are presented as mean ± standard error of the mean (SEM), with significance defined as p \ 0.05.
Results
CYD0692 inhibits HSC proliferation more potently than oridonin
Chemical structure of CYD0692 as compared to oridonin is shown in Fig. 1 . HSC proliferation and activation are determinants of its fibrogenic potential. To explore the antifibrotic effects of CYD0692 in comparison with oridonin, Alamar Blue assay was used to assess the viability of LX-2 cells after CYD0692 and oridonin treatment, respectively. As shown in Fig. 2a, CYD0692 significantly reduced LX-2 cell viability in a dose-dependent manner. Importantly, CYD0692 was significantly more potent with a calculated IC 50 value of 0.70 lM compared to that of oridonin (i.e., 7.5 lM). Figure 2b demonstrates that CYD0692 significantly decreased LX-2 cell viability at 24, 48, and 72 h as compared to the control. To further confirm these findings, the anti-proliferative effect of CYD0692 was significantly more potent (Fig. 2c) than oridonin in the rat hepatic stellate cell line HSC-T6. Next, C3A cells were used to assess the cytotoxic effects of CYD0692 on human hepatocytes. C3A, a clonal derivative of HepG2 cells, were used for their more normal hepatocyte phenotype [18, 19] . Illustrated in Fig. 2d, CYD0692 had no significant impact on cell viability over a range of concentrations, being comparable to oridonin. In summary, CYD0692 significantly attenuated activated hepatic stellate cell viability without cytotoxic effects on hepatocytes.
CYD0692 induces LX-2 cell cycle arrest
To examine the anti-proliferative mechanism of CYD0692, cell cycle progression in LX-2 cells was determined using flow cytometry. CYD0692 treatment at 24 h resulted in a significant increase in S-phase arrest compared to the 0.1 % DMSO control ( Fig. 3a; 30.12 ± 0.34 vs. 35.89 ± 0.77, p = 0.02). Since the majority of cells were in G 0 -G 1 phase under normal conditions, we did not synchronize cells before flow cytometry.
Next, we assessed the effect of CYD0692 on cell cycle regulatory proteins through Western Blot analyses (Fig. 3b,  c) . CYD0692 treatment resulted in a significant increase in phosphorylated-p53, while no change in total p53 was observed. Further, there was a significant decrease in Cyclin B1 expression at 8 h, which continued throughout the study period. In addition, p21 levels were significantly increased at 8-24 h. CYD0692 had no significant effect on C3A cell proliferation at our target dose (0.75 lM). To examine the possible mechanism of this effect, immunoblot assay was performed to assess the expression of p53 and p21. CYD0692 had no significant effect on p53 or p21 expression levels (Fig. 3d) .
CYD0692 promotes LX-2 cell apoptosis
Using the Cell Death Detection ELISA, LX-2 cell apoptosis was evaluated to determine whether apoptosis was involved in decreased HSC viability. The Cell Death Detection ELISA measures the cytosolic histone fragments, which are a hallmark of apoptosis [20] . CYD0692 treatment resulted in a significant increase in apoptosis at 48 h (Fig. 4a) . This was confirmed with Yo-Pro-1 staining, which detects early apoptosis [21] . Figure 4b demonstrates that vehicle-treated cells were negative for Yo-Pro-1 staining, while CYD0692-treated cells stained positive at 24 h, indicating early apoptosis. Using Western Blot analyses, cleaved caspase-3 and cleaved-PARP levels were found to be significantly increased at 24 h post-treatment (Fig. 4c) . However, CYD0692 had no significant effect on caspase-9 (data not shown).
CYD0692 suppresses endogenous and TGF-binduced extracellular matrix protein expression
The activated HSC is a central player in the development of fibrosis. A hallmark of HSC activation is over expression of a-SMA and increased production of Type I Collagen and fibronectin. The effects of CYD0692 on endogenous a-SMA and ECM production were assessed by Western Blot analysis. LX-2 cells were treated with CYD0692 for 24, 48, and 72 h and total cellular protein was isolated for analysis. CYD0692 decreased a-SMA expression at 48 and 72 h (Fig. 5a ). Fibronectin and Type I Collagen expression were significantly decreased at alltime points (Fig. 5b) . MMP-3, an ECM degradation protein, had significantly elevated expression at 4, 8, 12, and 16 h after treatment with CYD0692 (Fig. 5c ). TGF-b is one of the most potent stimulators of ECM production in hepatic fibrosis [22] . We examined the effects of CYD0692 on the TGF-b signaling cascade and TGF-b-induced ECM protein production. As shown in Fig. 5d , TGF-b treatment significantly increased the production of phosphorylatedSmad 2/3, phosphorylated-ERK 1/2 and fibronectin. Two hour pretreatment with CYD0692 significantly inhibited the production of phosphorylated-Smad 2/3 and fibronectin and reduced the expression of phosphorylated-ERK 1/2 to basal levels.
Discussion
We have previously reported that oridonin is capable of inhibiting HSC proliferation, inducing S-phase cell cycle arrest, enhancing HSC apoptosis, attenuating endogenous ECM protein production, and blocking TGF-b-stimulated ECM protein production [12] . CYD0692, a newly designed analog of oridonin, has been identified to be about tenfold more potent than oridonin with an IC 50 value of 0.70 lM, while having minimal effect on C3A cell viability. CYD0692 caused a significant increase in S-phase cell cycle arrest and demonstrated elevated phospho-p53 and p21 levels with decreased cyclin B1. Additionally, CYD0692 caused a significant increase in LX-2 cell apoptosis in a caspase-3-dependent mechanism. We found that CYD0692 mitigated endogenous production of a-SMA and ECM proteins type I collagen and fibronectin as well as inhibited the downstream signaling of the TGF-b pathway with decreased levels of pSmad 2/3, pERK 1/2, and fibronectin. S-phase arrest is initiated when DNA synthesis is incomplete and p53 is a major player in this checkpoint [23] . For cells progressing to mitosis Cdc2 must bind cyclin B1 and activate Cdc25, and this pathway is inhibited by activation of p53 and the subsequent increase in p21. p21 directly inhibits Cdc2 and p53 represses cyclin B1, leading to cycle arrest [23, 24] . CYD0692 may inhibit DNA synthesis and prevent the proliferation of HSC by activating p53 and increasing p21 levels, while having no effect on hepatocytes. Notably, from our results, C3A cell treatment with identical concentrations (0.75 lM) had no effect on p53 or p21 expression, therefore, C3A cell viability was not affected by CYD0692. This may implicate the important role of the p53/p21 pathway in HSC proliferation. Further, CYD0692 results in an increase in HSC apoptosis as evidenced by histone fragment accumulation and Yo-Pro-1 staining, as well as increased activation of cleaved caspase-3 and cleaved-PARP. This is different from the proposed mechanism for oridonin. Oridonin appears to work through a caspase-3-independent mechanism with increased expression of cleaved caspase-9 and cleaved-PARP [12] . This pathway for oridonin's apoptotic effects has been demonstrated in another study [25] .
CYD0692 has the capacity to suppress the expression of a-SMA, type I collagen, and fibronectin production at much lower concentrations when compared to oridonin. This finding provides preliminary evidence that CYD0692 may be a novel more potent agent for reducing hepatic fibrosis than its parent compound, oridonin. TGF-b is a major stimulant of hepatic fibrosis. TGF-b binds its receptor and activates a cascade of proteins, of which, Smad 2/3 is the major effector in the activation of the fibrogenic pathway [26] . The ERK pathway is another downstream signaling cascade triggered by TGF-b binding, where TGF-b binds its receptor and activates Ras, which then phosphorylates ERK 1/2 allowing for phosphorylation of Smad 2/3 [27] . CYD0692 inhibited the phosphorylation of Smad 2/3 and reduced the phosphorylation of ERK 1/2 leading to a decrease in fibronectin production. Furthermore, CYD0692 increased the expression of mmp-3. This could also lead to decreased ECM deposition and a decreased fibrosis. Further study into the anti-fibrogenic effects of CYD0692 is warranted to elucidate its exact mechanism of action.
Oridonin has been used in East Asian folk medicine for hundreds of years for its anti-bacterial and anti-inflammatory properties. More recently, oridonin has been extensively studied in the cancer literature for its promising effects on cancer biology [13, [28] [29] [30] [31] . Unfortunately, there is a paucity of data on the toxicity of oridonin and the few studies that have been published illustrate that oridonin may cause anemia, thrombotic events, and immunosuppression. Further, oridonin possesses only a moderate potency due to its relative insolubility in water [13, 15, 32, 33] . CYD0692 may offer several advantages over oridonin by being significantly more potent, having better cell permeability, and possibly less toxic effects.
Conclusion
In conclusion, CYD0692 has demonstrated potent antifibrotic properties in vitro, indicating its therapeutic potential as a novel safer anti-fibrogenic agent. Further investigation using an in vivo liver fibrosis model, such as carbon tetrachloride (CCL 4 ) or thioacetamide (TAA), is deemed necessary to validate whether CYD0692 will act as a viable, clinically relevant therapy for hepatic fibrosis.
